SCHEMBL30203403

SCHEMBL30203403

COC(=O)c1ccc([N+](=O)[O-])cc1C(=O)OC

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 6/20 0.56
MAPT P10636 5/20 0.53
HTT P42858 4/20 0.52
POLB P06746 2/20 0.51
KMT2A Q03164 3/20 0.50
MEN1 O00255 2/20 0.50
LMNA P02545 2/20 0.50
SMN1; SMN2 Q16637 1/20 0.50
PKM P14618 2/20 0.49
TDP1 Q9NUW8 2/20 0.49
NPSR1 Q6W5P4 2/20 0.49
NPC1 O15118 2/20 0.49
CTSV O60911 1/20 0.49
CTSL P07711 1/20 0.49
HSP90AA1 P07900 1/20 0.49
PAX8 Q06710 1/20 0.49
L3MBTL1 Q9Y468 1/20 0.49
CYP3A4 P08684 1/20 0.49
ALOX15 P16050 1/20 0.49
GAA P10253 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1403472 1.00 ALDH1A1 (0.56) ALDH1A1MAPTHTTPOLBKMT2A
Methane SCHEMBL27588822 0.98 ALDH1A1 (0.54) ALDH1A1MAPTHTTPOLBKMT2A
SCHEMBL16951683 0.92 ALDH1A1 (0.52) ALDH1A1MAPTHTTPOLBKMT2A
SCHEMBL8423567 0.92 MAPT (0.60) ALDH1A1MAPTHTTPOLBKMT2A
SCHEMBL27629995 0.92 MAPT (0.60) ALDH1A1MAPTHTTPOLBKMT2A
SCHEMBL25336874 0.92 ALDH1A1 (0.52) ALDH1A1MAPTHTTPOLBKMT2A
SCHEMBL8423562 0.92 MAPT (0.60) ALDH1A1MAPTHTTPOLBKMT2A
SCHEMBL11547738 0.90 ALDH1A1 (0.51) ALDH1A1MAPTHTTPOLBKMT2A
SCHEMBL11997805 0.89 ALDH1A1 (0.50) ALDH1A1MAPTHTTPOLBKMT2A
SCHEMBL12494510 0.89 ALDH1A1 (0.50) ALDH1A1MAPTHTTPOLBKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4622967-A1 COMPOUNDS THAT INHIBIT PKMYT1 Exelixis, Inc. (US) 2025-10-01 EP disclosed
CN-119684303-A Heterocyclic compound of difunctional degradable androgen receptor and application thereof 上海超阳药业有限公司 2025-03-25 CN disclosed
WO-2024112853-A1 COMPOUNDS THAT INHIBIT PKMYT1 EXELIXIS, INC. (US) 2024-05-30 WO disclosed
US-20230036854-A1 HETEROCYCLIC SPIRO-COMPOUNDS AS AM2 RECEPTOR INHIBITORS THE UNIVERSITY OF SHEFFIELD (GB) 2023-02-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230036854-A1 HETEROCYCLIC SPIRO-COMPOUNDS AS AM2 RECEPTOR INHIBITORS MC2R, AGTR2, NR3C2 ALDH1A1 2923/4885MAPT 4655/4885HTT 2536/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.